Paros Bio · Boston, Massachusetts LinkedIn

Paros Bio · Boston

Gene therapy for neurodegenerative diseases

A gene replacement approach to treat Autosomal Dominant Alzheimer’s Disease (ADAD).

  • AAV gene replacement
  • PSEN1 mutations
  • Preclinical
  • Boston, MA

The problem

Rare, genetic, and unambiguous

While the vast majority of Alzheimer’s disease is sporadic in nature with unknown etiology, there are rare genetic forms — autosomal dominant Alzheimer’s disease, ADAD.

The most common form is caused by loss-of-function mutations in the presenilin 1 gene (PSEN1). Paros Bio is creating a gene therapy to treat ADAD caused by mutations in PSEN1, that will directly address the underlying genetic cause of this disease.

The company anticipates that this novel approach will be a first-in-class treatment for ADAD, with the potential to slow or halt the progression of this devastating disease.

From the company’s own site
70–80%of ADAD cases are caused by PSEN1 mutations
<1%of all Alzheimer’s disease is ADAD
100+PSEN1 mutations identified as causative for ADAD

A genetic approach

Replace the mutant gene

ADAD is caused by mutations in one of three genes, with PSEN1 accounting for 70–80% of cases. The lead programme focuses on patients harbouring PSEN1 mutations and seeks to introduce an AAV gene therapy vector expressing a wildtype PSEN1 gene to replace the mutant form found in ADAD patients.

Read the science

Transformative therapies for ADAD

A genetically defined patient population, and a disease with well-described biomarkers.